Are Diabetic Kidney Disease and Diabetic Retinopathy Autoimmune?: Chronic, Low-grade Inflammatory Activity That Accelerates Microvascular Injury

What if the real driver of diabetic kidney disease and retinopathy isn’t sugar alone—but chronic inflammation triggered by the immune system?For decades, patients with diabetes have been taught that strict glucose control would protect their kidneys and eyes. Yet many who kept their A1c low, followed diets faithfully, and exercised consistently still developed kidney failure or vision loss.Why?In this thought-provoking book, Dr. Elliott Grant examines emerging evidence suggesting that Diabetic Kidney Disease (DKD) and Diabetic Retinopathy (DR) are not simply mechanical consequences of high glucose. Instead, they may represent autoimmune inflammatory disorders—conditions in which the body’s own immune responses contribute to microvascular damage in the kidneys and retinas.Drawing from peer-reviewed research, Dr. Grant explains how excess glucose forms Advanced Glycation End Products (AGEs) that lodge in sensitive tissues. These AGEs can act as persistent immune triggers, promoting ongoing inflammation even after blood sugar and A1c values normalize.The result:Chronic, low-grade inflammatory activity that accelerates microvascular injury.Dr. Grant explores why some individuals with diabetes remain protected while others are more vulnerable—focusing on genetics, antioxidant defenses, and biochemical pathways that either buffer or amplify inflammation.He also discusses parallels to well-known autoimmune diseases such as rheumatoid arthritis, Crohn’s disease, and psoriasis, where immune-modulating approaches are routinely used to limit long-term damage.Drawing on this perspective, Dr. Grant reviews research on existing FDA-approved medications—some long off-patent—that are being investigated for their ability to influence inflammatory pathways relevant to diabetic complications. These include therapies commonly used in cardiovascular, renal, or rheumatologic care. He encourages physicians and patients to consider whether current treatment strategies fully address the inflammatory dimensions of diabetic microvascular disease.This book is not medical advice.It is an invitation to examine new scientific questions, broaden clinical conversations, and reconsider how we understand the progression of diabetic complications.“Patients—you can learn, you can question, and you can participate in your own care.”— Elliott Grant, MD Read more